Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CVS HEALTH CORPORATION

(CVS)
  Report
Delayed Nyse  -  04:00:02 2023-02-03 pm EST
85.77 USD   -0.48%
02/03S&P 500 Posts Weekly Climb Led by Communication Services, Technology Sectors as FOMC Slows Rate Increases
MT
02/02Mailing abortion pills could break law, Republican AGs tell pharmacies
RE
02/01AbbVie's Humira gets a U.S. rival, but costs could stay high
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 96 64989 399136 274112 699112 699-
Enterprise Value (EV)1 159 446146 192179 925151 974148 858148 105
P/E ratio 14,6x12,5x17,3x28,7x11,4x10,5x
Yield 2,69%2,93%1,94%2,54%2,64%2,76%
Capitalization / Revenue 0,38x0,33x0,47x0,36x0,35x0,35x
EV / Revenue 0,62x0,54x0,62x0,48x0,46x0,46x
EV / EBITDA 9,23x8,07x9,20x7,55x7,24x7,16x
Enterprise Value (EV) / FCF 15,3x10,9x11,4x13,7x13,0x12,3x
FCF Yield 6,52%9,19%8,75%7,32%7,71%8,15%
Price to Book 1,51x1,29x1,81x1,56x1,45x1,38x
Nbr of stocks (in thousands) 1 300 9641 308 9131 321 0001 313 9671 313 967-
Reference price (USD) 74,368,310385,885,885,8
Announcement Date 02/12/202002/16/202102/09/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 256 776268 706292 111314 696325 826320 677
EBITDA1 17 27418 10819 56520 12220 55620 686
Operating profit (EBIT)1 15 33916 00817 31217 52517 72918 247
Operating Margin 5,97%5,96%5,93%5,57%5,44%5,69%
Pre-Tax Profit (EBT)1 8 9979 77010 4205 49713 99914 317
Net income1 6 6347 1797 9104 37010 03310 535
Net margin 2,58%2,67%2,71%1,39%3,08%3,29%
EPS2 5,085,465,952,997,538,19
Free Cash Flow1 10 39113 42815 74511 12111 47312 069
FCF margin 4,05%5,00%5,39%3,53%3,52%3,76%
FCF Conversion 60,2%74,2%80,5%55,3%55,8%58,3%
Dividend per Share2 2,002,002,002,182,272,37
Announcement Date 02/12/202002/16/202102/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 76 82680 63681 15976 37179 05482 677
EBITDA1 5 0705 4314 8254 5525 0065 418
Operating profit (EBIT)1 4 4834 8104 2333 9834 4164 840
Operating Margin 5,84%5,97%5,22%5,22%5,59%5,85%
Pre-Tax Profit (EBT)1 2 9464 029-4 4562 9443 4484 022
Net income1 2 3122 951-3 4162 1382 5422 949
Net margin 3,01%3,66%-4,21%2,80%3,22%3,57%
EPS2 1,742,23-2,601,611,972,15
Dividend per Share2 0,550,550,550,550,560,56
Announcement Date 05/04/202208/03/202211/02/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 62 79756 79343 65139 27536 15935 406
Net Cash position1 ------
Leverage (Debt / EBITDA) 3,64x3,14x2,23x1,95x1,76x1,71x
Free Cash Flow1 10 39113 42815 74511 12111 47312 069
ROE (Net Profit / Equities) 15,1%14,8%15,5%16,1%15,5%15,8%
Shareholders' equity1 43 80948 51051 17427 18864 74366 710
ROA (Net Profit / Asset) 4,41%4,35%4,82%4,08%4,08%4,29%
Assets1 150 315164 974164 261107 147246 053245 491
Book Value Per Share2 49,153,056,955,059,062,1
Cash Flow per Share2 9,8512,113,78,8710,712,2
Capex1 2 4572 4372 5202 8683 0203 037
Capex / Sales 0,96%0,91%0,86%0,91%0,93%0,95%
Announcement Date 02/12/202002/16/202102/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 112 698 942 042
Net sales (USD) 292 111 000 000
Number of employees 258 000
Sales / Employee (USD) 1 132 213
Free-Float 74,5%
Free-Float capitalization (USD) 84 012 743 167
Avg. Exchange 20 sessions (USD) 988 000 931
Average Daily Capital Traded 0,88%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA